Status:
UNKNOWN
Intra-nasal Dexmedetomidine for Children Undergoing MRI Imaging
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
British Columbia Children's Hospital
Conditions:
MRI Sedation
Eligibility:
All Genders
3-18 years
Phase:
PHASE4
Brief Summary
This study aims to assess the use of intranasal dexmedetomidine (IN-dex) as a sole agent in aiding the successful completion of a MRI scans in children. Dexmedetomidine, a routinely used anesthetic ag...
Detailed Description
Purpose: To assess the use of IN-dex as a sole agent in aiding the successful completion of a MRI scan in children. Hypothesis: We hypothesize that the optimal dose for IN-dex to produce appropriat...
Eligibility Criteria
Inclusion
- ASA 1 or 2
- Scheduled for elective MRI scan on the general anesthesia list
- Child Life MRI simulation score of 6-10 (Figure 1)
- Age 3 - 18
Exclusion
- Taking existing opioid, sedative, or cannabinoid medication
- Severe learning disability defined as the inability to follow simple commands
- Severe Cardiac disease
- Chronic hypertension
- Allergy to dexmedetomidine
- Nasal anatomical abnormality
- Known or anticipated difficult airway
Key Trial Info
Start Date :
February 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03806777
Start Date
February 1 2019
End Date
October 1 2020
Last Update
January 25 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.